CYDI has already been known to reverse merge... Check below..
"On February 10, 2005, (the "Closing Date") the Company closed on an Agreement and Plan of Merger (the "Agreement") among Certron Corporation ("Certron"), a California corporation, Certron Acquisition Corp., a Maryland corporation and a wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a Maryland corporation ("Cybrdi - Maryland") relating to the acquisition by Certron of all of the issued and outstanding capital stock of Cybrdi -Maryland in exchange for shares of common stock of Certron that will aggregate approximately 93.8% of the issued and outstanding common stock of Certron. Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being the surviving corporation, (b) the common stock of Cybrdi-Maryland has been cancelled and converted into the right to receive shares of the common stock of Certron at an exchange ratio of 1.566641609 per share. This resulted in the issuance of 47,328,263 shares of the Certron's common stock, and (c) each share of the common stock of Acquisition Sub has been converted in to and become one share of the common stock of Cybrdi-Maryland. The share exchange has been accounted for as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi, Inc. will be treated as the continuing entity for accounting purposes and the historical financial statements presented will be those of Cybrdi, Inc."
Cybrdi Inc.. The Group's principal activity is of biotechnology manufacturing and research and development. Through Chaoying Biotech, it also controls SD Chaoying, a cultural and entertainment company with a special license for casino gambling. It manufactures both human and animal tissue micro-array for a wide variety of scientific uses, including drug discovery and development. Its products and services include TISSUE MICROARRAYS (TMA): TMA technology can survey hundreds or even thousands of clinical specimens in a single experiment utilizing common probes, including DNA, RNA, peptide, protein and antibody probes. It currently offers a wide variety of tissue array products and services on the commercial market, including approximately 234 different disease and 98 different organ types of both human and animal varieties. It operates in the United States and China. The Group has distributors in the United States, Canada, Germany, Italy, Belgium, Japan and Taiwan.
News 
Market Data 
Discover 
